Novel therapeutic approaches for classic galactosemia currently (defined as: in the last 5 years) being explored aim either to (i) restore GALT activity, (ii) influence the cascade of events or (iii) address the clinical picture. This evidence concerns the gene GALT and classic galactosemia.